Drug Profile


Alternative Names: Ara-C asparagine conjugate; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; Cytarabine asparagine conjugate

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioSight
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Preclinical Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 20 Sep 2017 BioSight completes a phase I/II trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia in Israel (NCT02544438)
  • 09 Aug 2017 BioSight completes enrolment in its phase I/II trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia in Israel
  • 02 Jun 2017 Updated efficacy and safety data from a phase I/II trial in Acute myeloid leukaemia and Acute lymphocytic leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top